A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

Not yet recruiting · NCT07663838 · Registry updated 2026-06-23

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)	Bacterial Infections and Mycoses, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Infections, Urogenital Diseases, bacterial infectious disease, bacterial vaginosis, female reproductive system disorder, vaginal disorder, vaginitis	Not yet recruiting	Phase 1	2026-06-23		NCT07663838

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Changchun GeneScience Pharmaceutical Co., Ltd.	50

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Tsinghua Changgung Hospital	Beijing	China	31
Jiangxi Provincial Women and Children's Medical Center	Nanchang	China	1
Nanjing Maternity and Child Health Care Hospital	Nanjing	China	2
Shandong Provincial Hospital	Jinan	China	1
The First Hospital of Jilin University	Changchun	China	110
The Second Hospital of Shanxi Medical University	Taiyuan	China	10
Tianjin Medical University General Hospital	Tianjin	China	61